US Study Shows AstraZeneca-Oxford Vaccine Prevents 100% Hospitalization, Effective For Adults

US Study Shows AstraZeneca-Oxford Vaccine Prevents 100% Hospitalization, Effective For Adults

The AstraZeneca-Oxford Covid-19 vaccine has received a shot in the arm when a study claimed that the drug is effective for all adults. The data obtained during the US study said that the vaccine in the phase-3 trial showed an efficacy rate of 79 percent in preventing infection. It said that taking the vaccine reduces the risk of hospitalization significantly. The scientific name of the vaccine is AZD1222. It is developed by Oxford University and AstraZeneca. The study has contradicted several European nations’ claims that the vaccine is not effective. Several countries stopped its distribution. They claimed that it causes serious side-effects and doesn’t work on people above 65 years of age.

The US trial of the vaccine included 32,000 people. More than 20 percent of the participants were above 65 years. The phase-3 trial showed 80 percent efficacy on this group of people. People above 65 are the most vulnerable to contracting the infection. According to the company’s claim, the vaccine is 100 percent effective in preventing hospitalization. The trial results were reviewed by Data Safety Monitoring Board. It is an independent agency. It said that vaccine has no safety issues. The trial didn’t show evidence of blood clotting risks. Several European nations had claimed that the vaccine is causing blood clots and stopped using the drug.

Notably, the emergency use of the AstraZeneca-Oxford vaccine was approved by the European Medical Agency. The agency too junked the claims of a blood clot. Subsequently, Germany, France, Italy, and other countries resumed the distribution of the vaccine. The US study has only reposed faith in the vaccine. The US regulator is yet to approve the drug for emergency use. The vaccine required a separate trial in the US before it is rolled out for public use. The World Health Organization has already granted emergency use authorization to the vaccine. AstraZeneca said that its drug is a viral vector vaccine. The drug is made with a harmless virus. It produces a harmless protein to boost the immune system to fight against the virus.

Maria Waddy

I fell into writing about healthcare shortly after graduation, where I realized that I didn't want to work in a laboratory for the rest of my life! My main areas of interest are the nerve impulses between parts of the body, brain and behavior, nerve cells and fibres as well as what influences the decisions we make about our health and how we can change it over time. I studied Biopsychology at Vassar College and got my Ph.D. in Biopsychology and Behavioral Neuroscience at CUNY's Graduate Center in New York City.

Leave a Reply

Your email address will not be published. Required fields are marked *